Arvinas, Inc. pioneers the development of targeted protein degraders, a novel therapeutic modality designed to address classically "undruggable" targets. The company's lead clinical candidates include vepdegestrant, an estrogen receptor degrader for breast cancer, and bavdegalutamide, an androgen receptor degrader for prostate cancer. Beyond oncology, Arvinas is advancing a pipeline of neurology programs targeting proteins implicated in diseases such as Parkinson's and progressive supranuclear palsy. The company operates primarily in the United States and funds its research through strategic collaborations with major pharmaceutical companies, including Pfizer, Genentech, and Bayer. As a clinical-stage entity, Arvinas generates revenue primarily through upfront payments, research and development funding, and milestone payments from these partnerships.
